drugset / Trial / NCT00509210

Study of Telaprevir in Subjects With Hepatic Impairment

NCT00509210

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to assess the safety and pharmacokinetics of Telaprevir following administration of multiple oral doses to subjects with moderate and severe hepatic impairment.

Timeline

Start
2007-09
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Telaprevir Small molecule Oral

Indications